Dermatological toxicity of imatinib mesylate.
Prasad
N
N
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India 400012.
Deshmukh
C
C
Biswas
G
G
Bakshi
A
A
Sastry
P S R K
PS
Parikh
P M
PM
D000328:Adult; D001549:Benzamides; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000188:drug therapy; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate